Literature DB >> 17498894

Therapeutic approaches targeting the prion receptor LRP/LR.

Chantal Zuber1, Heike Ludewigs, Stefan Weiss.   

Abstract

Transmissible spongiform encephalopathies known as prion diseases are a group of fatal neurodegenerative disorders that affect both humans and animals. The generally accepted principle of the disease is that the conversion of the cellular prion protein (PrP(c)) into the disease associated isoform PrP(Sc) leads to spongiform degeneration of the brain and amyloid plaque formation. Until now no therapy leading to potential alleviation or even cure of the disease exists. It is therefore important to develop therapeutic approaches for the treatment of TSEs since these infections are inevitably fatal and, especially in the case of vCJD, they affect youngsters. Besides current conventional therapeutic strategies, this review summarizes new therapeutic tools targeting the prion receptor LRP/LR.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17498894     DOI: 10.1016/j.vetmic.2007.04.005

Source DB:  PubMed          Journal:  Vet Microbiol        ISSN: 0378-1135            Impact factor:   3.293


  5 in total

Review 1.  De novo mammalian prion synthesis.

Authors:  Federico Benetti; Giuseppe Legname
Journal:  Prion       Date:  2009-10-26       Impact factor: 3.931

Review 2.  Therapies for human prion diseases.

Authors:  Peter K Panegyres; Elizabeth Armari
Journal:  Am J Neurodegener Dis       Date:  2013-09-18

Review 3.  Recent advances in prion chemotherapeutics.

Authors:  Valerie L Sim; Byron Caughey
Journal:  Infect Disord Drug Targets       Date:  2009-02

4.  Anti-LRP/LR antibody W3 hampers peripheral PrPSc propagation in scrapie infected mice.

Authors:  Chantal Zuber; Gerda Mitteregger; Claudia Pace; Inga Zerr; Hans A Kretzschmar; Stefan Weiss
Journal:  Prion       Date:  2007-07-07       Impact factor: 3.931

5.  siRNA-mediated silencing of the 37/67-kDa high affinity laminin receptor in Hep3B cells induces apoptosis.

Authors:  Tharinee Susantad; Duncan R Smith
Journal:  Cell Mol Biol Lett       Date:  2008-04-18       Impact factor: 5.787

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.